Given the high sequence and functional homology between p53 and p63, it has been shown that the small compound APR246/PRIMA-1MET, capable of restoring the wild-type conformation to mutant p53 and inducing apoptosis in cancer cells, (clinical trial phase I/II, [51]), was also able to re-establish the p63 activity in primary cells of EEC patients. Here, TP53 is linked to cancer.